A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT04309474
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 121 participants
- Sponsor
- Registry
-
NCT04309474 -
2019-003753-29
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Japan, South Korea, Spain
- Registry status
- Completed
Technical summary
Registry record NCT04309474. Randomized; triple masking; primary purpose treatment. Start 2020-11-09 (actual); primary completion 2024-04-18 (actual). Results posted on 2025-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
- Acronym
- EAISE
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Elezanumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- AbbVie
Record details
- Record id
cardio:ct-nct04309474- Content hash
c9f50fff304c93e0021aba046d4dcf269d758825f2efdec21b313f1ebeed9795